BioStem Technologies (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced the ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. With no fresh headline event driving attention to BioStem Technologies (BSEM), recent ...

POMPANO BEACH, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of ...

The webcast will feature an overview of the quarter from BioStem Technologies management. To register for the event, please click HERE. About BioStem Technologies, Inc. (OTC: BSEM): BioStem ...

POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech ...

Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies on initial and secondary public ...

POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of ...

Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally. Discoveries made are more than value drivers for the companies behind them; they can be ...

BioStem Technologies Inc. company and executive profile by Barron's. View the latest BSEM company infomation and executive bios.

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or ...